Gastrointestinal stromal tumor

World Journal of Surgical Oncology

Volumn 7, Issue , 2009, Pages 61-

  Stamatakos, Michael ^a   Douzinas, Emmanouel ^a   Stefanaki, Charikleia ^a   Safioleas, Panagiotis ^a   Polyzou, Electra ^a   Levidou, Georgia ^b   Safioleas, Michael ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FLAVOPIRIDOL; IMATINIB; KI 67 ANTIGEN; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; TANESPIMYCIN;

ABDOMINAL BLEEDING; ABDOMINAL MASS; ABDOMINAL PAIN; CANCER INCIDENCE; CANCER RESISTANCE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DERMATITIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; ENDOSCOPIC ECHOGRAPHY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEMOPERITONEUM; HUMAN; HYPOTHYROIDISM; INFLAMMATION; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVER DYSFUNCTION; MULTIPOTENT STEM CELL; MUSCLE CRAMP; MYALGIA; NAUSEA; NEEDLE BIOPSY; NEUTROPENIA; OVERALL SURVIVAL; PERIORBITAL EDEMA; PIGMENTATION; PROGNOSIS; REVIEW; SIDE EFFECT; STOMACH ULCER; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR REGRESSION; VITILIGO; GASTROINTESTINAL TUMOR; PATHOLOGY;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS;

EID: 70350710463     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-7-61     Document Type: Review

References (72)

1. Agaram NP, Besmer P, Wong CC, Guo T, Socci ND, Maki RG, De Santis D, Brennan MF, Singer S, De Matteo RP, Antonescu CR. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin Cancer Res 2007, 13(1):170-181. 10.1158/1078-0432.CCR-06-1508, 17200352.
2. Joensuu H. Gastrointestinal stromal tumor (GIST). Annals of Oncology 2006, 17(10):280-286.
3. Mazur MT, Clark HB. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507-519.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580. 10.1126/science.279.5350.577, 9438854.
5. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Surgical resection of gastrointestinal stromal tumor after treatment with imatinib. Ann Surg Oncol 2006, 14:14-24.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710. 10.1126/science.1079666, 12522257.
7. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, Kang DY. Gastrointestinal Stromal Tumor Committee; The Korean Gastrointestinal Pathology Study Group. Gastrointestinal Stromal Tumors in Koreans: Incidence and the Clinical, Pathologic and Immunohistochemical Findings. J Korean Med Sci 2005, 20:977-984. 10.3346/jkms.2005.20.6.977, 16361808.
8. Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005, 117:289-293. 10.1002/ijc.21167, 15900576.
9. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer 2005, 41:2868-2872. 10.1016/j.ejca.2005.09.009, 16293410.
10. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100:162-168. 10.1111/j.1572-0241.2005.40709.x, 15654796.
11. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001, 438:1-12. 10.1007/s004280000338, 11213830.
12. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465. 10.1053/hupa.2002.123545, 12094370.
13. Nilsson BP, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005, 103:821-829. 10.1002/cncr.20862, 15648083.
14. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005, 55:106-112. 10.1111/j.1440-1827.2005.01806.x, 15743318.
15. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004, 22:3813-3825. 10.1200/JCO.2004.05.140, 15365079.
16. Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL. Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol 2008, 16:241-250. 10.1177/1066896907306967, 18573781.
17. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib. J Clin Oncol 2005, 23:5357-5364. 10.1200/JCO.2005.14.068, 15928335.
18. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR, Ware CB, Woodell J. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005, 65:6631-6639. 10.1158/0008-5472.CAN-05-0891, 16061643.
19. Akahoshi K, Sumida Y, Matsui N, Masafumi O, Akinaga R, Kubokawa M, Motomura Y, Honda K, Watanabe M, Nagaie T. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound - guided fine needle aspiration. World J Gastroenterol 2007, 13(14):2077-2082.
20. Jamali F, Darwiche S, El-Kinge N, Tawil A, Sowed A. Disease progression following Imatinib failure in gastrointestinal stromal tumors: Role of surgical therapy. The Ongologist 2007, 12:438-442.
21. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58. 1420965, 10636102, 10.1097/00000658-200001000-00008.
22. Shah P, Gao F, Edmundowicz SA, Azar RR, Early DS. Predicting Malignant Potential of Gastrointestinal Stromal Tumors Using Endoscopic Ultrasound. Dig Dis Sci 2009, 54:1265-1269. 10.1007/s10620-008-0484-7, 18758957.
23. Chak A, Canto MI, Rösch T, Dittler HJ, Hawes RH, Tio TL, Lightdale CJ, Boyce HW, Scheiman J, Carpenter SL, Van Dam J, Kochman ML, Sivak MV. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc 1997, 45:468-473. 10.1016/S0016-5107(97)70175-5, 9199902.
24. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000, 46:88-92. 1727785, 10601061, 10.1136/gut.46.1.88.
25. Kinoshita K, Isozaki K, Tsutsui S, Kitamura S, Hiraoka S, Watabe K, Nakahara M, Nagasawa Y, Kiyohara T, Miyazaki Y, Hirota S, Nishida T, Shinomura Y, Matsuzawa Y. Endoscopic ultrasonography-guided fine needle aspiration biopsy in follow-up patients with gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 2003, 15(11):1189-1193. 10.1097/00042737-200311000-00007, 14560152.
26. Gupta P, Tewari M, Shulka H. Gastrointestinal stromal tumor. Surg Oncol 2008, 17(2):129-138. 10.1016/j.suronc.2007.12.002, 18234489.
27. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423. 10.1016/S0140-6736(01)06535-7, 11705489.
28. Safdar A, Sher A. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). GENE 2007, 401:38-45. 10.1016/j.gene.2007.06.017, 17659849.
29. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005, 29:52-68. 10.1097/01.pas.0000146010.92933.de, 15613856.
30. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002, 20:3898-905. 10.1200/JCO.2002.03.095, 12228211.
31. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Iesalnieks I, Dirnhofer S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tornillo L. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005, 11:638-645.
32. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Løberg EM, Isaksen V, Eide TJ, Nielsen TO. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol 2008, 21:46-53. 10.1038/modpathol.3800976, 17917670.
33. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999, 23:82-87. 10.1097/00000478-199901000-00009, 9888707.
34. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007, 38:679-687. 10.1016/j.humpath.2007.03.001, 17437861.
35. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59:4297-4300.
36. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M. Mutations in gastrointestinal stromal tumors-a population-based study from Northern Norway. APMIS 2007, 115:289-298. 10.1111/j.1600-0463.2007.apm_587.x, 17504295.
37. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134. 10.1016/S0140-6736(04)17098-0, 15451219.
38. Rankin C, Von Mehren M, Blanke C. Dose effect of imatinib in patients with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004, 23:815.
39. Parfitt J, Streutker C, Riddell R, Driman D. Gastrointestinal stromal tumors: A contemporary review. Pathology - Research and Practice 2006, 202:837-847.
40. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, DeiTos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566-578. 10.1093/annonc/mdi127, 15781488.
41. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004, 127:294-299. 10.1053/j.gastro.2004.02.021, 15236194.
42. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, Rijn M, Schnipper LE, Demetri GD. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005, 23:2735-2743. 10.1200/JCO.2005.06.009, 15837988.
43. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastrointestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg after progression on 400 mg - an international, intergroup study of the EORTC, ISG and AGITG. Proc Am Soc Clin Oncol 2004, 23:815.
44. Demetri GD, van Oosterom AT, Blackstein M, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005, 23:308s.
45. Dematteo RP, Heinrich MC, el-Rifai WM, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466-477. 10.1053/hupa.2002.124122, 12094371.
46. Abdulkader I, Cameselle-Teijeiro J, Forteza J. Pathological changes related to imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Histopathology 2005, 46:470-472. 10.1111/j.1365-2559.2005.02014.x, 15810964.
47. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25:1107-1113. 10.1200/JCO.2006.09.0183, 17369574.
48. Dogan SS, Esmaeli B. Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal Stromal Tumor. Hematol Oncol Clin North Am 2009, 23(1):109-114. 10.1016/j.hoc.2008.11.003, 19248974.
49. Cerchione C, Fabbricini R, Pane F, Luciano L. Vitiligo-like lesions in an adult patient treated with Imatinib Mesylate. Leukemia Research 2009, 33:e104-105. 10.1016/j.leukres.2008.12.023, 19232719.
50. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. British Journal of Cancer 2008, 99:448-454. 2527784, 18665181, 10.1038/sj.bjc.6604497.
51. Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatology Online Journal 2008, 4(7):7.
52. Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa T, Kojima Y, Ojima T, Ikeya S, Nakayama H, Sugai Y, Hiwatashi N, Asano S. Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate. Nippon Shokakibyo Gakkai Zasshi 2008, 105:1619-1626.
53. Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors. Hematol Oncol Clin North Am 2009, 3(1):97-107.
54. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targ Oncol 2009, 4:99-105.
55. Demetri GD, von Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
56. Loughrey MB, Mitchell C, Mann M, Michael GB, Waring PM. Gastrointestinal stromal tumor treated with neoadjuvant imatinib. J Clin Pathol 2005, 58:779-781. 1770717, 15976351, 10.1136/jcp.2004.023226.
57. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: potential diagnostic pitfall. Histopathology 2005, 47:41-47. 10.1111/j.1365-2559.2005.02179.x, 15982322.
58. Basu S, Balaji S, Bennett D, Davies N. Gastrointestinal stromal tumors (GIST) and laparoscopic resection. Surg Endosc 2007, 21:1685-1689. 10.1007/s00464-007-9445-z, 17661137.
59. Efremidou E, Liratzopoulos N, Papageorgiou M, Romanidis K. Perforated GIST of the small intestine as a rare cause of acute abdomen: Surgical treatment and adjuvant therapy. Case report. J Gastrointestin Liver Dis 2006, 15(3):297-299.
60. Tsukuda K, Hirai R, Miyake T, Takagi S, Ikeda E, Kunitomo T, Tsuji H. The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute. Surgery today 2007, 37:953-957. 10.1007/s00595-007-3535-3, 17952524.
61. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR, Besmer P. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal tumor. Proc Natl Acad Sci USA 2006, 103:12843-12848. 1568935, 16908864, 10.1073/pnas.0511076103.
62. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR, Besmer P. Gastrointestinal stromal tumors in a mouse model by target mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003, 100:6706-6711. 164511, 12754375, 10.1073/pnas.1037763100.
63. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal tumor. Cancer Res 2006, 66:9153-9161. 10.1158/0008-5472.CAN-06-0165, 16982758.
64. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren MGodwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. PNAS 2008, 105:8387-8392. 2448846, 18550829, 10.1073/pnas.0803383105.
65. Ponsaing L, Hansen MB. Therapeutic procedures fir submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007, 13(24):3316-22.
66. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004, 10:3076-3081. 10.1158/1078-0432.CCR-03-0581, 15131046.
67. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004, 202:430-438. 10.1002/path.1546, 15095270.
68. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
69. Kim T, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors. The Oncologist 2009, 14:540-547. 10.1634/theoncologist.2008-0145, 19411681.
70. Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, Halpren Z, Wassermann I, Halevy A. Gastrointestinal Stromal Tumors: A 19 Year Experience. IMAJ 2009, 11:98-102.
71. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). EJSO 2009, 35:739-745.
72. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Abbeele AD. CT and PET: early indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR 2007, 189:W324-330. 10.2214/AJR.07.2496, 18029844.